MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumours (MK-7684A-005)

Official Title

A Multicentre, Open-label, Phase 2 Basket Study of MK-7684A, a Co-formation of Vibostolimab (MK-7684) With Pembrolizumab (MK-3475), With or Without Other Anticancer Therapies in Participants With Selected Solid Tumours

Summary:

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumours. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
  • Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR
  • ORR per RECIST 1.1 as Assessed by Investigator
Secondary Outcome:
  • Overall Survival (OS)
  • PFS per RECIST 1.1 as Assessed by Investigator
  • Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR
  • DOR per RECIST 1.1 as Assessed by Investigator
  • Change from Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30)
  • Change from Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5)
  • Number of Participants Who Experienced One or More Adverse Events (AEs)
  • Number of Participants Who Discontinued Study Intervention Due to an AE

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society